Compare GXO Logistics Inc (GXO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GXO Logistics Inc vs ResMed Inc. — how do they compare? GXO Logistics Inc trades at $53.31 (market cap $6.02B), while ResMed Inc. trades at $200.21 (market cap $28.80B). The key difference: ResMed Inc. is far larger — about 4.8× GXO Logistics Inc's market cap, and ResMed Inc. pays a 1.21% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.
| GXO | RMD | |
|---|---|---|
Market Cap | $6.02B | $28.80B |
Sector | Industrials | Health |
52-Week High | $65.59 | $293.73 |
52-Week Low | $45.52 | $182.82 |
Enterprise Value | $11.18B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GXO Logistics (GXO) trades at $53.69, up 8.09% in the last session, with a bullish technical signal and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, including Q1 2026, and reported Q1 2026 revenue growth of 10.8% year-over-year. Positive news includes new partnership renewals and an upcoming Investor Day, reinforcing its position as the world's largest pure-play contract logistics provider.
The outlook is positive, with a consensus price target of $66.60 implying significant upside. Investment opportunities stem from operational growth and strategic focus on high-margin sectors, but risks include competitive pressures from Amazon and reliance on the retail sector. Earnings on August 5, 2026, will be a key catalyst.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
